FDA action counts
| Total FDA actions | 1 |
|---|---|
| Warning letters | 0 |
| Recalls | 0 |
| Approval records | 1 |
| Form 483 inspection citations | 0 |
| Most recent action | September 3, 2026 |
Risk pattern analysis
Argus HQ analysis — not an FDA finding
This section is Argus HQ analysis, not an FDA finding. HANDA ONCOLOGY, LLC has 1 FDA event on file. A pattern across multiple FDA touchpoints does not by itself establish that any specific product currently poses a risk; it reflects only the frequency of FDA engagement with this company as recorded in Argus HQ's database. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed. Argus HQ does not independently verify FDA's underlying findings; this page summarizes what FDA has published and links back to the original FDA source for each event. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures.
Enforcement history
On 2026-09-03, Argus HQ recorded an FDA approval for HANDA ONCOLOGY, LLC, rated "info" severity in Argus HQ's classification: HANDA ONCOLOGY, LLC — NDA approval: Unspecified (unspecified). Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed.
Frequently asked questions
- How many FDA actions has HANDA ONCOLOGY, LLC had?
- Argus HQ has recorded 1 FDA events for HANDA ONCOLOGY, LLC: 0 warning letters, 0 recalls, 1 approvals, and 0 Form 483 inspection observations. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures.
- What is the most recent FDA action against HANDA ONCOLOGY, LLC?
- The most recent FDA event Argus HQ has on file for HANDA ONCOLOGY, LLC is dated 2026-09-03, with a severity rating of "info" in Argus HQ's classification. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures.
- Does Argus HQ track new FDA actions for HANDA ONCOLOGY, LLC automatically?
- Yes. Argus HQ ingests FDA sources daily, including FDA warning letters, recalls, drug and biologic approvals, and Form 483 inspection observations. When a new FDA action linked to HANDA ONCOLOGY, LLC is observed, this page's event count and history update automatically.
- How many FDA actions does Argus HQ track for HANDA ONCOLOGY, LLC?
- 1 total: 0 warning letters, 0 recalls, 1 approval record, and 0 Form 483 inspection citations.
Every FDA action tied to this company, the week it happens.
Free weekly briefing. Real-time alerts on paid plans.
Related enforcement actions
Compare with
Two different companies merged onto this page by mistake? Or a name variant missing? Tell us — corrections@argushq.ai
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Verified from FDA.gov · Last updated: Sep 3, 2026Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). FDA Actions Against HANDA ONCOLOGY, LLC. Digital Empire Holdings LLC. Retrieved from https://argushq.ai/company/handa-oncology-llc
"FDA Actions Against HANDA ONCOLOGY, LLC." Argus HQ Research, Digital Empire Holdings LLC, 2026, argushq.ai/company/handa-oncology-llc.
Argus HQ Research. "FDA Actions Against HANDA ONCOLOGY, LLC." Digital Empire Holdings LLC. Accessed September 11, 2026. https://argushq.ai/company/handa-oncology-llc.
@misc{argushq_argushq_ai_company_handa_oncology_llc_2026,
title = {FDA Actions Against HANDA ONCOLOGY, LLC},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire Holdings LLC},
url = {https://argushq.ai/company/handa-oncology-llc},
note = {Accessed: September 11, 2026}
}Source: FDA.gov (aggregated across Warning Letters, Recalls, Approvals, Form 483s) ↗

